HCA Corporation
HCA
$429.69
+0.78%
HCA Healthcare, Inc. is a leading healthcare provider organization operating the largest collection of acute-care hospitals in the United States, with a network of 190 hospitals and over 2,500 outpatient facilities across 19 states and a small presence in the United Kingdom. The company is a dominant market leader in the for-profit hospital industry, distinguished by its massive scale, geographic diversification, and integrated care delivery model. The current investor narrative centers on the stock's resilience and long-term demographic tailwinds from an aging population, juxtaposed against near-term pressures from labor costs, regulatory scrutiny, and volatile patient mix, as evidenced by recent industry commentary highlighting both strong operational trends and policy headwinds.…
HCA
HCA Corporation
$429.69
Related headlines
Investment Opinion: Should I buy HCA Today?
Rating: Hold. The core thesis is that HCA is a fundamentally strong company caught in a cyclical downdraft, presenting a potential opportunity for patient investors, but near-term risks advise caution before establishing new positions.
The Hold rating is supported by a mix of attractive and concerning data points. Positively, the forward P/E of 13.07x represents a discount to the sector, the PEG ratio of 0.56 indicates undervalued growth, and TTM free cash flow of $7.69 billion is exceptionally strong. However, these are counterbalanced by severe technical weakness (down 11.30% in 3 months), high financial leverage (Debt/Equity: -8.33), and decelerating revenue growth (6.72% YoY). Analyst sentiment is bullish (8 Buys), suggesting the current price weakness may be overdone.
The two biggest risks that could invalidate a future Buy thesis are: 1) a sustained break below the key $330 support level, signaling a deeper fundamental problem, and 2) a further deceleration in revenue growth below 5% YoY, calling into question the demographic growth story. This Hold would upgrade to a Buy if the forward P/E compressed to near 11x (offering a larger margin of safety) or if quarterly revenue growth re-accelerates above 8% while margins stabilize. It would downgrade to a Sell if leverage increases meaningfully or if the stock breaks below $330. Relative to its own history and sector peers, HCA appears fairly valued to slightly undervalued, but not compellingly cheap given the clear near-term headwinds.
Sign up to view all
HCA 12-Month Price Forecast
The AI assessment is neutral based on a conflict between durable long-term strengths and acute near-term weaknesses. The company's scale, cash flow, and demographic positioning are undeniable assets, but they are currently overshadowed by high leverage, cost pressures, and broken price momentum. The base case is the most probable, suggesting a period of sideways consolidation. Confidence is medium due to the high volatility (beta 1.37) and leverage, which increase outcome variance. The stance would upgrade to bullish on evidence of sustained margin stabilization and a technical reversal above key resistance. It would downgrade to bearish on a breakdown below $330 or a material deterioration in free cash flow.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Corporation's 12-month outlook, with a consensus price target around $558.60 and implied upside of +30.0% versus the current price.
Average Target
$558.60
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$344 - $559
Analyst target range
Analyst coverage for HCA is robust, with recent institutional ratings from ten major firms showing a strong bullish bias, including eight 'Buy' or 'Outperform' ratings and two 'Neutral' or 'Equal Weight' ratings, indicating a consensus leaning heavily positive. The full target price range is not explicitly provided in the data, but the high degree of recent reaffirmations from firms like TD Cowen, Mizuho, and UBS suggests analysts see the recent price weakness as a buying opportunity, with the low target likely incorporating regulatory risks and the high target banking on operational execution and demographic trends; the wide dispersion in historical P/E ratios underscores the underlying uncertainty in the sector that can lead to divergent price targets.
Bulls vs Bears: HCA Investment Factors
The investment debate for HCA hinges on a clash between its strong fundamental cash-generating engine and its deteriorating technical and near-term operational momentum. The bull case is anchored in its scale, profitability, discounted valuation, and supportive analyst sentiment. The bear case is driven by its high leverage, decelerating growth, severe recent price breakdown, and industry-wide headwinds. Currently, the bearish evidence from price action and leverage appears more immediate and pressing, though the bullish fundamentals provide a compelling long-term foundation. The single most important tension is whether the company's robust free cash flow and operational scale can overcome the significant financial leverage and cost pressures before investor sentiment deteriorates further.
Bullish
- Robust Free Cash Flow & Shareholder Returns: HCA generates exceptional free cash flow, with TTM FCF of $7.69 billion. This strong cash generation supports aggressive shareholder returns and provides a buffer for debt management and strategic investments.
- Strong Profitability & Scale Advantage: The company maintains high profitability with a Q4 gross margin of 41.9% and a net margin of 9.62%. Its massive scale, with 190 hospitals and 2,500 outpatient sites, provides significant operational leverage and pricing power with payers.
- Attractive Valuation with Forward P/E Discount: HCA trades at a forward P/E of 13.07x, which is below typical sector averages for healthcare facilities. This valuation, coupled with a PEG ratio of 0.56, suggests the market is not pricing in its growth potential.
- Analyst Consensus Strongly Bullish: Recent institutional ratings show a strong bullish bias, with 8 out of 10 analysts issuing 'Buy' or 'Outperform' ratings. This consensus indicates professional confidence in the company's ability to navigate near-term headwinds.
Bearish
- Severe Technical Downtrend & High Volatility: The stock is in a sharp downtrend, down 8.78% over the past month and 11.30% over three months. It trades just 22.2% above its 52-week low, and its beta of 1.37 indicates 37% higher volatility than the market, amplifying downside risk.
- Significant Financial Leverage & Weak Liquidity: HCA's balance sheet shows high leverage with a negative debt-to-equity ratio of -8.33, indicating substantial debt obligations relative to equity. Its current ratio of 0.83 points to modest short-term liquidity to cover liabilities.
- Revenue Growth Deceleration & Cost Pressure: Q4 revenue growth of 6.72% YoY marks a slowdown from prior double-digit rates. Concurrently, net margin compressed from 9.18% in Q1 2025 to 9.62% in Q4, reflecting ongoing pressure from labor and other operating costs.
- Industry Headwinds: Patient Mix & Regulation: Recent news from peer Tenet Healthcare highlights industry-wide pressure from unfavorable patient insurance mix, which can pressure revenue and margins. HCA also faces persistent regulatory scrutiny and policy uncertainty.
HCA Technical Analysis
The stock is in a pronounced downtrend from its recent highs, trading at $433.09, which is only 22.2% above its 52-week low of $330 and 22.2% below its 52-week high of $556.52, positioning it in the lower quartile of its annual range and signaling significant technical weakness. Despite a positive 1-year price change of 26.25%, the recent momentum is decisively negative, with a 1-month decline of 8.78% and a 3-month drop of 11.30%, indicating a sharp reversal from the longer-term uptrend and suggesting a breakdown in bullish sentiment. Key technical support is at the 52-week low of $330, while resistance lies at the recent highs near $556; a sustained break below support could trigger further selling, while the stock's beta of 1.37 indicates it is 37% more volatile than the broader market, amplifying both downside risk and potential recovery moves.
Beta
1.19
1.19x market volatility
Max Drawdown
-21.8%
Largest decline past year
52-Week Range
$330-$557
Price range past year
Annual Return
+18.3%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | -13.3% | +8.6% |
| 3m | -19.2% | +6.7% |
| 6m | -9.2% | +9.8% |
| 1y | +18.3% | +26.6% |
| ytd | -8.7% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
Revenue growth remains steady but is decelerating, with Q4 2025 revenue of $19.51 billion representing a 6.72% year-over-year increase, though this marks a slowdown from the double-digit growth seen in prior periods, driven primarily by its core Managed Care and Other Insurers segment which contributed $9.54 billion. The company is highly profitable, with Q4 2025 net income of $1.88 billion and a gross margin of 41.9%, and while the net margin of 9.62% is solid, it shows some compression from the 9.18% in Q1 2025, reflecting ongoing cost pressures. HCA generates robust cash flow, with trailing twelve-month free cash flow of $7.69 billion, supporting aggressive shareholder returns, but its balance sheet carries significant leverage as indicated by a negative debt-to-equity ratio of -8.33 and a current ratio of 0.83, pointing to high financial obligations relative to equity and modest short-term liquidity.
Quarterly Revenue
$19.5B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.41%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Given its substantial net income, the primary valuation metric is the P/E ratio. The trailing P/E stands at 15.88x, while the forward P/E is lower at 13.07x, indicating the market expects earnings growth to continue. Compared to sector averages, HCA's valuation presents a mixed picture; its forward P/E of 13.07x is below the typical healthcare facilities average (often in the mid-teens), suggesting a discount, while its EV/EBITDA of 10.05x is also reasonable for the industry. Historically, the stock's current trailing P/E of 15.88x is near the middle of its own multi-year range, which has seen peaks above 20x and troughs below 12x, implying the current multiple does not price in extreme optimism nor deep pessimism, but rather a balanced view of its steady earnings profile.
PE
15.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
HCA faces substantial financial and operational risks, primarily stemming from its highly leveraged balance sheet. With a negative debt-to-equity ratio of -8.33 and a current ratio of 0.83, the company has significant financial obligations and modest liquidity. This leverage could constrain financial flexibility, especially if interest rates remain elevated. Operationally, revenue growth is decelerating to 6.72% YoY, and net margins show signs of compression, indicating that cost pressures, particularly from labor, are not fully being offset by pricing or volume gains.
Market and competitive risks are elevated due to HCA's current technical breakdown and high market correlation. The stock's beta of 1.37 means it is 37% more volatile than the broader market, amplifying downside moves during sector-wide sell-offs. Valuation compression is a key risk; while its forward P/E of 13.07x appears reasonable, a further de-rating could occur if growth continues to slow. Competitive and regulatory pressures are persistent, as highlighted by Tenet Healthcare's recent commentary on unfavorable patient mix impacting sales, a headwind that likely affects HCA as well.
The worst-case scenario involves a combination of a severe economic downturn reducing elective procedures, a spike in labor costs compressing margins further, and rising interest rates increasing its debt servicing burden. This could trigger multiple compression and force the company to divert cash flow from shareholder returns to debt management. In this adverse scenario, the stock could realistically re-test its 52-week low of $330, representing a downside of approximately -24% from the current price of $433.09. The historical max drawdown of -20.77% provides a benchmark for the volatility inherent in the name.
FAQ
The key risks, ranked by severity, are: 1) Financial Risk: High leverage with a negative debt-to-equity ratio (-8.33) and weak short-term liquidity (current ratio 0.83). 2) Operational Risk: Decelerating revenue growth and margin pressure from labor costs, as seen in net margin compression. 3) Market Risk: High stock volatility (beta 1.37) and severe recent technical breakdown, indicating negative momentum. 4) Industry Risk: Unfavorable patient insurance mix and ongoing regulatory scrutiny, as highlighted by recent peer commentary.
The 12-month forecast presents three scenarios. The Base Case (50% probability) targets $480-$520, assuming stable execution and range-bound trading. The Bull Case (30% probability) targets $556-$600, requiring successful cost management and a sentiment reversal. The Bear Case (20% probability) targets $330-$400, involving worsening headwinds and a test of the 52-week low. The Base Case is most likely, anchored by the company's strong cash flow but capped by its leverage and growth deceleration. The key assumption is that revenue growth stabilizes and margins do not deteriorate further.
HCA appears fairly valued to slightly undervalued based on standard metrics. Its forward P/E of 13.07x is below typical healthcare facility peers, and its PEG ratio of 0.56 suggests the market is undervaluing its growth. However, this discount is justified by its high debt load and decelerating revenue growth (6.72% YoY). The valuation implies the market expects mid-single-digit earnings growth with persistent cost headwinds, but is not pricing in a major operational breakdown. Compared to its own historical P/E range, the current multiple is near the middle, indicating a balanced, not euphoric, sentiment.
HCA presents a nuanced opportunity. For long-term, patient investors, its discounted valuation (forward P/E of 13.07x), strong free cash flow ($7.69B TTM), and dominant market position are attractive. However, it is not a good buy for risk-averse or short-term investors due to its high financial leverage, recent severe price decline (-11.30% in 3 months), and ongoing industry cost pressures. A good entry point would be on further weakness closer to strong support at $330, providing a larger margin of safety against the -24% downside risk to that level.
HCA is primarily suitable for a long-term investment horizon of 3-5 years. Its value proposition is based on demographic tailwinds and scale advantages that play out over time. The stock's high beta (1.37) and recent volatility make it a poor candidate for short-term trading. Furthermore, its minimal dividend yield (0.63%) does not support an income strategy. Investors should be prepared to hold through cyclical downturns to capture the potential upside from its discounted valuation and cash flow generation. A minimum holding period of 18-24 months is suggested to allow for operational improvements and a potential re-rating.